160730-57-4

Usage

Uses

Used in Pharmaceutical Applications:
(8beta,10xi)-2-bromo-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline is used as a key compound in the development of medications for central nervous system disorders. Its investigation into potential effects on dopamine receptors makes it a promising candidate for therapeutic agents for conditions such as Parkinson's disease and schizophrenia.
Used in Neuroscience Research:
In the field of neuroscience, (8beta,10xi)-2-bromo-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline is utilized as a research tool to study the brain and its functions. Its interaction with dopamine receptors provides valuable insights into the underlying mechanisms of various neurological conditions and aids in the development of novel treatment strategies.

Upstream product

• 288-88-0 1,2,4-Triazole 
• 162070-43-1 (5R,8S,10R)-2-bromo-6-methyl-8-ergolinylmethyl p-toluenesulfonate 
• 115178-30-8 (6aR,9S,10aR)-7-Methyl-9-[1,2,4]triazol-1-ylmethyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of new (5R,8S,10R)-ergoline derivatives with antihypertensive of dopaminergic activity

A series of new (5R,8S,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were evaluated in conscious spontaneously hypertensive rats and in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra, respectively. (5R,8S,10R)-6-Methyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8S,10R)-8-(1-Imidazolylmethyl)-6-methylergoline (5a, BAM-2101) and (5R,8S,10R)-2-bromo-6-methyl-8-(1,2,4-triazol-1-ylmethyl)ergoline (7c, BAM-2202) exhibited potent antihypertensive activities. The maximum falls of systolic blood presure after oral administration of 5a and 7c at 3 mg/kg were 95 and 132 mmHg, respectively, while those of cianergoline, bromocriptine mesylate, hydralazine, and nifedipine at the same dose were 40, 37, 47, and 49 mmHg, respectively. The durations of significant antihypertensive effects of these compounds except nifedipine were more than 7 h. None of the ergolines exhibited potent dopaminergic activity. Structure-activity relationships are discussed.